Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04155775 · ClinicalTrials.gov registry record · NA

Effects of a Platelet Transfusion Best Practices Alert

A NA study of Thrombocytopenia, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
446
Enrollment target
1
Study location

NCT04155775: Completed NA study of Thrombocytopenia, sponsored by Stanford University.

NCT04155775 is a NA study of Thrombocytopenia that has completed, run by Stanford University. The registered enrollment target is 446 participants, above the 290-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04155775, a NA study of Thrombocytopenia, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
446 participants
Enrollment target
1
Study location

Study Summary

This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion societies such as the AABB (formerly American Association of Blood Banks).

Primary Outcome

Number of platelet transfusions occurring in patients with recent platelet counts above 50k/uL

Conditions Studied

Interventions

  • OTHER Computer electronic health record alert (Best Practice Alert - BPA)

Study Locations (1)

California

  • Stanford Healthcare - Stanford

Trial Details

FieldValue
Enrollment Target 446 participants
Start Date 2019-05-09
Est. Completion 2020-02-04
Phase NA
Stanford University

1,744 total trials

What the finished NCT04155775 record still lists

NCT04155775 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, above the 290-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (54% higher).

The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Computer electronic health record alert (Best Practice Alert - BPA) is the first listed.

NCT04155775 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04155775 about?

NCT04155775 is a clinical study titled "Effects of a Platelet Transfusion Best Practices Alert". This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion societies such as the AABB (formerly American Association of Blood Banks).

What is the current status of trial NCT04155775?

This trial is currently completed. It is a NA study. The enrollment target is 446 participants. The study started on 2019-05-09. Estimated completion is 2020-02-04.

What conditions does trial NCT04155775 study?

This clinical trial studies the following conditions: Thrombocytopenia.

What interventions are being tested in trial NCT04155775?

The interventions under investigation include: Computer electronic health record alert (Best Practice Alert - BPA) (OTHER).

Who is sponsoring clinical trial NCT04155775?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04155775 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thrombocytopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04155775's enrollment target sits among peer trials

446 4th of 20 higher than 17 of 20 other Thrombocytopenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04065399 · 447 participants · Phase 1

    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04155775, the US trial registry maintained by the National Library of Medicine. NCT04155775 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.